Last reviewed · How we verify

Neurontin — Competitive Intelligence Brief

Neurontin (Gabapentin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiepileptic/Analgesic. Area: Oncology.

marketed Antiepileptic/Analgesic α2δ subunit of voltage-activated calcium channels Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Neurontin (Gabapentin) — Pfizer Inc.. Gabapentin binds with high-affinity to α2δ subunit of voltage-activated calcium channels; precise mechanism unknown.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Neurontin TARGET Gabapentin Pfizer Inc. marketed Antiepileptic/Analgesic α2δ subunit of voltage-activated calcium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiepileptic/Analgesic class)

  1. Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Neurontin — Competitive Intelligence Brief. https://druglandscape.com/ci/neurontin. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: